Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: Long-term case-control follow-up study
Reference (43)
- et al.
Cyclophosphamide and malignancy
Lancet
(1977) - et al.
Transitional cell carcinoma of the bladder associated with cyclophosphamide
J Urol
(1974) - et al.
Cyclophosphamide
J Urol
(1975) Cyclophosphamide cystitis and bladder cancer: a hypothesis
Eur J Cancer Clin Oncol
(1979)- et al.
The incidence of bladder cancer after cyclophosphamide therapy
J Urol
(1979) - et al.
Excess risk of lymphoma, leukemia, and myeloma in patients with rheumatoid arthritis
J Chronic Dis
(1978) - et al.
Cyclosporin A in immunosuppression, Epstein-Barr antibody, and lymphoma
Lancet
(1980) - et al.
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine steroid therapy
Lancet
(1984) - et al.
Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort
Am J Med
(1985) - et al.
Treatment of rheumatoid arthritis with nitrogen mustard: preliminary report
JAMA
(1951)
Long-term cyclophosphamide therapy in rheumatoid arthritis
Arthritis Rheum
(1968)
Controlled trial of cyclophosphamide in rheumatoid arthritis
N Engl J Med
(1970)
Double-blind study of cyclophosphamide in rheumatoid arthritis
Arthritis Rheum
(1972)
Comparison of high- and low-dose cyclophosphamide therapy in rheumatoid arthritis
Arthritis Rheum
(1980)
Does drug therapy slow radiographic deterioration in rheumatoid arthritis?
N Engl J Med
(1983)
Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs
Br Med J
(1979)
Immunosuppression and cancer
Transplant Proc
(1973)
Toxicity of antineoplastic agents
Adv Cancer Res
(1975)
Second malignant neoplasms associated with immunosuppressive medication
Cancer
(1976)
Neoplasia and cyclophosphamide
Arthritis Rheum
(1973)
Carcinoma of the urinary bladder in patients receiving cyclophosphamide
N Engl J Med
(1975)
Cited by (233)
Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders
2023, Journal of the Neurological SciencesAKT Signaling Downstream of KGF Is Necessary and Sufficient for Blocking Cyclophosphamide Bladder Injury
2022, American Journal of PathologyThe cancer risk according to three subtypes of ANCA-associated vasculitis: A propensity score-matched analysis of a nationwide study: Cancer risk in AAV three subtypes
2021, Seminars in Arthritis and RheumatismCitation Excerpt :In a study conducted in four institutions in 2011, 1-, 2-, and 5-year survival rates improved 88%, 85%, and 78%, respectively [7]. While CYC has greatly improved the survival rate in AAV, it can lead to adverse events including renal toxicity, bone marrow suppression, opportunistic infection, hemorrhagic cystitis, and an increased occurrence of cancer [7–10]. Several studies have reported that the incidence of cancer increases in patients with AAV [7,8,11–17].
Loss of Fibroblast Growth Factor Receptor 2 (FGFR2) Leads to Defective Bladder Urothelial Regeneration after Cyclophosphamide Injury
2021, American Journal of PathologyOverall and site-specific cancer before and after diagnosis of idiopathic inflammatory myopathies: A nationwide study 2002–2016
2021, Seminars in Arthritis and Rheumatism
This work was supported in part by the Arthritis Foundation, Western Pennsylvania Chapter.
- *
Current address: 4944 Penn Avenue South, Minneapolis, Minnesota 55409.
Copyright © 1987 Published by Excerpta Medica Inc.